One injection, lipoprotein(a) down 97% at 48 weeks - in 70 healthy volunteers

Design

first-in-human, randomised, double-blind, placebo-controlled phase 1, seven dose cohorts

Population

70 otherwise healthy adults aged 18-55 with raised lipoprotein(a); median age 27.5

Primary outcome

investigator-assessed adverse events within 24 weeks

Effect

no drug-related adverse events; median lipoprotein(a) reduction at 48 weeks 53% (9 mg) to 97% (600 mg)

Raised lipoprotein(a) is associated with atherosclerotic cardiovascular disease and is not meaningfully modified by any current lipid treatment. A first-in-human phase 1 trial at a single Chinese site randomised 70 otherwise healthy adults aged 18 to 55 with raised lipoprotein(a) to a single subcutaneous dose of a long-acting small interfering RNA or placebo, 8:2, across seven dose cohorts from 9 mg to 600 mg.

The primary endpoint was safety. Adverse events occurred in 53%, mostly grade 1-2 and judged unrelated to the drug; there were no injection-site reactions, no serious adverse events, no drug-related adverse events and no deaths. Median lipoprotein(a) reduction at 48 weeks ranged from 53% (IQR -71 to -41) at 9 mg to 97% (-98 to -97) at 600 mg. In the cohort enrolled with baseline concentrations above 200 nmol/L, 225 mg produced a 96% median reduction, an absolute fall of 208 nmol/L.

The duration is the striking part - a single injection still suppressing the target at 48 weeks - and it is also why this is research rather than practice. Participants were young, healthy volunteers with no cardiovascular disease. Lipoprotein(a) is a biomarker, and no trial has yet shown that lowering it prevents events. Until one does, the honest statement to a patient with a high level is that a drug that shifts the number exists in early testing and the outcome question is unanswered.

• Nothing changes in clinic: this is phase 1 safety and pharmacodynamic data in healthy volunteers.
• Do not start measuring lipoprotein(a) more often on the strength of this; the management question is still open.
• If a patient with known raised lipoprotein(a) asks, say the outcome trials have not been done.
• Watch for phase 2 dose selection at 225 mg or above, where suppression was durable.
• Median age 27.5 and no cardiovascular disease - the safety profile in older patients on multiple drugs is unknown.

Why it matters

It moves lipoprotein(a) from an unmodifiable risk marker to a modifiable one, which makes the unanswered outcome question suddenly worth answering.

Don't overread it

Lipoprotein(a) is a surrogate: lowering it by 97% has not been shown to prevent a single cardiovascular event.

The statistics, in plain English

These are medians with interquartile ranges, not means with confidence intervals, so they describe what happened in the middle of a very small group rather than estimating a population effect. With 57 people spread across seven dose cohorts, each cohort holds roughly eight - enough to detect a dramatic pharmacodynamic signal like 97% suppression, nowhere near enough to characterise uncommon harm.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.